AZ
Therapeutic Areas
Zai Lab Pipeline
| Drug | Indication | Phase |
|---|---|---|
| zocilurtatug pelitecan (ZL-1310) | Small Cell Lung Cancer (2L extensive-stage) | Phase 3 |
| ZL-1503 | Atopic Dermatitis | Phase (Early Clinical) |
| ZL-6201 | Solid Tumors | Phase (Early Clinical) |
| AUGTYRO™ (repotrectinib) | NTRK-Positive Solid Tumors | Approved |
| COBENFY® (xanomeline/trospium) | Schizophrenia | Approved |
| NUZYRA® (omadacycline) | CABP & ABSSSI | Commercial |
| QINLOCK® (ripretinib) | Advanced GIST | Commercial |
| Adagrasib | KRAS G12C-mutated NSCLC | Commercial/Approved |
Leadership Team at Zai Lab
SD
Samantha Du
Founder, Chairperson and Chief Executive Officer
RG
Rafael G. Amado
President, Head of Global Research and Development
PC
Prista Charuworn
Vice President, Global Clinical Development, Neuroscience & Immunology (NSI)
YC
Yajing Chen
Chief Financial Officer
CC
Christine Chiou
Senior Vice President, Head of Investor Relations
FT
F. Ty Edmondson
Chief Legal Officer and Corporate Secretary
SH
Shan He
Senior Vice President, Chief Business Officer
JS
Josh Smiley
President and Chief Operating Officer
JY
James Yan
Chief Operating Officer, Global R&D
JD
John D. Diekman
Board of Directors